Your Brain Was Simply Receiving the Wrong Signal
For most of your adult life, you’ve likely been fed a specific narrative: eat less, move more, and if the weight isn’t shifting, you aren’t trying hard enough. It is a story most of us believed because we didn’t have the tools to challenge it.
But here is the piece that usually gets left out: hunger isn’t a character flaw — it’s a hormonal signal. When that signal is disrupted, no amount of discipline can permanently close the gap. It isn’t about a lack of grit; it’s about a physiological mismatch.
The Communication Breakdown
Under normal circumstances, specialized cells in your gut release a hormone called GLP-1 (glucagon-like peptide-1) after you eat. This hormone travels via the vagus nerve to tell your brain that you’re finished. When this system is functioning correctly, appetite regulation happens without conscious effort. You eat, the signal fires, and you stop.
However, this “fullness” signal can weaken due to chronic stress, metabolic dysfunction, or the shifting biology that comes with age. When the brain stops hearing that message clearly, it continues to ask for fuel even when you’ve had enough.
You are then told the resulting hunger is your fault, when in reality, the feedback loop is simply broken.
Source: Müller TD et al., “Glucagon-like peptide 1 (GLP-1).” Molecular Metabolism, 2019. PMC6812410
Beyond the Stomach: The Reward System
The science becomes even more relevant when you look at where these receptors live.
GLP-1 receptors aren’t just located in the hypothalamus; they are distributed throughout the brain’s reward system — the mesolimbic pathway. This is the same circuitry that governs craving and the perceived “appeal” of food.
This means that when GLP-1 signaling is weak, food doesn’t just feel like fuel; it feels urgent and compelling. That 10 p.m. mental negotiation in the kitchen isn’t a sign of weakness; it’s a reward system operating without its natural hormonal counterbalance.
Modern GLP-1 receptor agonists work by reducing this “hedonic” value of food, which is a clinically distinct mechanism that actually changes long-term behavior.
Source: Dickson SL et al., “The role of the central GLP-1 receptor in food and drug reward.” Frontiers in Behavioral Neuroscience, 2012. PMC3796262
The “Over 40” Shift
For women, the decline of estrogen during perimenopause and menopause directly disrupts GLP-1 signaling and drives increased insulin resistance.
This is often why weight management feels fundamentally different after 40. It isn’t that your metabolism “slowed down” in a vague, general sense — it’s that the hormonal architecture moderating your appetite was restructured without your consent.
The circuit changed; you didn’t.
Source: Mauvais-Jarvis F et al., “The role of estrogens in insulin resistance.” Journal of Clinical Endocrinology & Metabolism, 2013.
How the Protocol Works
Treatments like Tirzepatide do not work by “forcing” restriction or artificially suppressing the appetite; they amplify the communication between gut and brain that was always meant to be there.
As a dual agonist, Tirzepatide activates both GLP-1 and GIP receptors. The GIP component is particularly vital here, as it addresses the insulin sensitivity issues that are often exacerbated by estrogen loss.
Data from the SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that participants achieved average weight reductions ranging from 16% to 22.5% depending on the dosage.
While these studies often highlight higher starting weights, the molecule is effective at lower weights as well, provided the dose is properly calibrated.
Source: Jastreboff AM et al., “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM, 2022. DOI: 10.1056/NEJMoa2206038
A Note on Lean Muscle
It is worth noting that GLP-1 protocols can result in the loss of lean muscle mass alongside fat.
For women over 40 already navigating age-related muscle decline, this is a critical factor. This is why physician oversight isn’t a formality in the SoSo Thin model — it is the entire point.
The right dose must be titrated, monitored, and adjusted to your specific baseline. That isn’t a premium service; it’s the minimum standard of care your biology deserves.
The protocol that works is the one built around you.
SoSo Thin
Weight Loss and Wellness Delivered.
References
- Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019; PMC6812410
- Dickson SL et al. The role of the central GLP-1 receptor in food and drug reward. Frontiers in Behavioral Neuroscience. 2012; PMC3796262
- Berthoud HR et al. Gut-brain communication and obesity. Annals of the New York Academy of Sciences. 2021
- Mauvais-Jarvis F et al. The role of estrogens in insulin resistance and metabolic disease. Journal of Clinical Endocrinology & Metabolism. 2013
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022; DOI: 10.1056/NEJMoa2206038
- Graczyk & Bisschops. GLP-1 receptor agonists in perimenopausal weight management. Cureus. January 2026. Herbert Wertheim College of Medicine, Miami
